NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avanzanite Bioscience

Avanzanite Bioscience

Private
AmsterdamHealthcare & Life Scienceshttps://www.avanzanite.com/

Last Round

Series A

Nov 18, 2025

Total Funding Raised

$37.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Avanzanite Bioscience is a specialty pharmaceutical company that provides a commercialization and distribution platform for biopharmaceutical partners to launch medicines for rare diseases across Europe.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain, Compliance

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

rare diseaseorphan drugorphan drug commercializationpharmaceutical commercializationmarket accessdrug distributionbiotech partnerpharma go-to-marketregulatory affairsEuropean market accessspecialty pharmapharma licensingreimbursement strategy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avanzanite Bioscience Comps

Public and private peers based on sector, stage, and business model.

Avanzanite Bioscience comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Avanzanite Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 18, 2025

Key People

Founding team and executive leadership

Adam Andrzej Plich

Founder CEO

Founding Team

Jason Cameron

Chief Technology Officer

Executive Team

Abdelghani Omari

CFO

Executive Team

Avanzanite Bioscience Investors

Notable investors and investment history

Avanzanite Bioscience investors
InvestorRounds
MVM Life Science Partners LLPSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Grew 17% QoQ, from 64 to 75 employees.

  • Mar 24, 2026

    Operations expanded in France with a new General Manager appointed.

Avanzanite Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avanzanite Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avanzanite Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmsterdam
Employee Range84
Year Founded2021
Last FundingNov 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.